Jump to main content
Jump to site search


CuS@PDA–FA Nanocomposites: A Dual Stimuli-responsive DOX Delivery Vehicle with Ultrahigh Loading Level for Synergistic Photothermal-chemotherapies on Breast Cancer

Abstract

In this study, CuS@PDA nanoparticles were synthesized and used to create a novel tumor-targeting nanocomposite platform composed of copper sulfide@polydopamine-folic acid/doxorubicin (CuS@PDA–FA/DOX) for performing both photothermal and chemotherapeutic cancer treatment. The nanocomposite platform has ultrahigh loading levels (4.2 ± 0.2 mg mg-1) and a greater photothermal conversion efficiency (η=42.7%) than CuS/PDA alone. An over expression of the folate receptor (FR) in MCF-7 cells allows for CuS@PDA–FA/DOX nanocomposites to favor interactions with them rather than non-cancerous cells that do not express the FR as readily. Under near infrared (NIR) irradiation, the CuS@PDA–FA/DOX system using a synergistic combination of photothermal therapy and chemotherapy yields a better therapeutic effect than either photothermal therapy or chemotherapy alone. The treatment is very effective with the cell viability is only 5.6 ± 1.4%.

Back to tab navigation

Supplementary files

Article information


Submitted
01 Nov 2019
Accepted
13 Jan 2020
First published
14 Jan 2020

J. Mater. Chem. B, 2020, Accepted Manuscript
Article type
Paper

CuS@PDA–FA Nanocomposites: A Dual Stimuli-responsive DOX Delivery Vehicle with Ultrahigh Loading Level for Synergistic Photothermal-chemotherapies on Breast Cancer

W. Chen, S. Zhang, X. Liu, Q. Sun, O. Johnson, T. Yang, M. Chen and J. Wang, J. Mater. Chem. B, 2020, Accepted Manuscript , DOI: 10.1039/C9TB02440A

Social activity

Search articles by author

Spotlight

Advertisements